 | F647
F647 is another anti-inflammatory small molecule compound designed to combat acute lung injury (ALI). SARS virus infection and lung cancer radiation therapy both cause acute lung injury, and in many cases, directly lead to patient death. With 300 million smokers in China alone, lung cancer cases are on up-swing and account for half of the whole world. In animal model studies, F647 showed strong efficacy to protect animal against drug induced lung damage and improved animal nutritional status. In May, 2005, the Company received Clinical Trial Permit from the Chinese State Food and Drug Administration. F647 has completed two multi-center Phase II clinical studies for Idiopathic Pulmonary Fibrosis and Radiation Pneumonitis. The Company is currently preparing for NDA filing for Idiopathic Pulmonary Fibrosis and Phase III trial for Radiation Pneumonitis. |
 | F351
The small molecule compound F351 (NCE), developed by the Company as a non-steroid anti-fibrosis drug, has shown strong efficacy for treating a broad range of fibrosis diseases, especially in liver. Liver disease is the so-called “National Disease” in China. 130 million people are affected in China alone due to HBV pandemic. In two animal studies, orally administered F351 significantly inhibited liver fibrosis and showed high level of safety. Major biochemical and pathological parameters associated with liver fibrosis returned to normal level after drug treatment in two animal models tested. In direct comparison with Chinese herb medicine that had shown efficacy in human trials, F351 was proved to be superior potency. F351 has low molecular weight, good solubility in water, and easy method to synthesize.No toxicity is observed in animal models at very high dosage. To develop this compound for liver fibrosis, the Company is currently conducting Phase I clinical study in the Peking Union Hospital. |
